Intellipharmaceutics International

Intellipharmaceutics International is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage form drugs. The company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a variety of existing and new drugs. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, and its product pipeline (some of which have received approval from the U.S. Food and Drug Administration ("FDA")) is at various stages of development. The company’s development pipeline includes Abbreviated New Drug Application ("ANDA") and New Drug Application ("NDA") 505(b)(2) candidates. These include the company’s abuse-deterrent extended-release oxycodone hydrochloride formulation ("Oxycodone ER") based on its proprietary nPODDDS™ Novel Point Of Divergence Drug Delivery System (for which an NDA has been submitted to the FDA), as well as Regabatin™ XR (pregabalin extended-release capsules).